A Novel Dendritic Cell Vaccine Targeting CD70 for Osteosarcoma Lung Metastases
The overall survival for patients with relapsed metastatic osteosarcoma (OS) remains stagnant at <25%. Dendritic cell vaccines (DCVs) induce antigen-specific anti-tumor immunity. We previously demonstrated that an ex vivo-generated DCV using CD103+ DCs (cDCs) and K7M3 OS lysates (K7M3 lysate-cDCV) induced systemic anti-tumor immunity. Targeting tumor-associated antigens (TAAs) using recombinant proteins offers a more efficient, tumor-independent alternative to using tumor lysates. CD70, a TAA, is overexpressed on multiple solid tumors including OS but not normal tissue. Incubation of cDCs with K7M3 lysates or recombinant CD70 in presence of poly I:C upregulated the expression of antigen-presenting and co-stimulatory molecules necessary for antigen presentation to T cells. The CD70-primed cDCs demonstrated comparable activity to K7M3 lysate-primed cDCs in inducing T-cell proliferation and IFNγ expression, and activating T-cell mediated tumor cell cytotoxicity. Using a bilateral subcutaneous tumor model, we showed that CD70-cDCV induced localized and systemic anti-tumor immune responses, inhibiting the growth of both the treated and untreated tumors. Pre-treatment with CD70-cDCV prevented the development of OS lung metastases and prolonged overall survival. Finally, intravenous administration of CD70-cDCV into mice with established OS lung metastases resulted in fewer and smaller lung tumors and improved survival. The CD70-cDCV demonstrated comparable anti-tumor activity to K7M3 lysate-cDCV. By contrast, no therapeutic activity was seen using lysates from CD70-knocked down K7M3 cells (CD70KD-cDCV), suggesting a critical role for CD70. Immunofluorescence staining of tumor-bearing lungs revealed increased infiltration of CD4 and CD8 T cells in mice treated with K7M3 lysate-cDCV or CD70-cDCV but not CD70KD-cDCV. Collectively, these findings indicate that targeting CD70 using a CD70-cDCV generates an effective anti-tumor response against OS and therefore serves as an alternative approach to using tumor lysates. CD70-cDCV may provide a new immunotherapeutic strategy against metastatic OS.
Authors
- Eugenie S. Kleinerman (ORCID: https://orcid.org/0000-0003-4280-3031)
- Yuanzheng Yang
- Pradeep Shrestha (ORCID: https://orcid.org/0000-0003-3418-6790)
- You Zhou
- Zhanglong Peng
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cells
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3390/cells15222099
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00